AR093767A1 - Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona y profarmacos de estos - Google Patents
Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona y profarmacos de estosInfo
- Publication number
- AR093767A1 AR093767A1 ARP130103390A ARP130103390A AR093767A1 AR 093767 A1 AR093767 A1 AR 093767A1 AR P130103390 A ARP130103390 A AR P130103390A AR P130103390 A ARP130103390 A AR P130103390A AR 093767 A1 AR093767 A1 AR 093767A1
- Authority
- AR
- Argentina
- Prior art keywords
- profarms
- fluoroalquil
- benzodiazepinona
- cyclopropyl
- bis compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- -1 -CH2OH Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
- C07D243/26—Preparation from compounds already containing the benzodiazepine skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto caracterizado por la fórmula (1) y/o al menos una sal de aquel, en donde: R¹ es -CH₂CH₂CF₃; R² es -CH₂CH₂CF₃ o -CH₂CH₂CH₂CF₃; R³ es H, -CH₃ o Rˣ; R⁴ es H o Rʸ; Rˣ es: -CH₂OC(O)CH(CH₃)NH₂, -CH₂OC(O)CH(NH₂)CH(CH₃)₂, -CH₂OC(O)CH((CH(CH₃)₂)NHC(O)CH(NH₂)CH(CH₃)₂, o un compuesto del grupo de fórmulas (2); Rʸ es: -SCH₂CH(NH₂)C(O)OH, -SCH₂CH(NH₂)C(O)OCH₃ o -SCH₂CH(NH₂)C(O)OC(CH₃)₃; el anillo A es fenilo o piridinilo; cada Rᵃ es independientemente Cl, alquilo C₁₋₃, -CH₂OH, -CF₃, ciclopropilo, -OCH₃ y/u -O(ciclopropilo); cada Rᵇ es independientemente F, Cl, -CH₃, -CH₂OH, -CF₃, ciclopropilo y/u -OCH₃; y es 0, 1 ó 2; y z es 0, 1 ó 2; siempre que si el anillo A es fenilo y z es 0, entonces y es 1 ó 2 y al menos un Rᵃ es alquilo C₁₋₃, -CH₂OH, -CF₃, ciclopropilo u -O(ciclopropilo); siempre que si R³ es Rˣ, entonces R⁴ es H; y siempre que si R⁴ es Rʸ, entonces R³ es H o -CH₃.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261703912P | 2012-09-21 | 2012-09-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR093767A1 true AR093767A1 (es) | 2015-06-24 |
Family
ID=49263506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130103390A AR093767A1 (es) | 2012-09-21 | 2013-09-20 | Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona y profarmacos de estos |
Country Status (34)
Country | Link |
---|---|
US (2) | US8999918B2 (es) |
EP (1) | EP2897945B1 (es) |
JP (1) | JP6165255B2 (es) |
KR (1) | KR102155588B1 (es) |
CN (1) | CN104703976B (es) |
AR (1) | AR093767A1 (es) |
AU (1) | AU2013317923B2 (es) |
BR (1) | BR112015005817B1 (es) |
CA (1) | CA2885574C (es) |
CL (1) | CL2015000711A1 (es) |
CO (1) | CO7310522A2 (es) |
CY (1) | CY1118739T1 (es) |
DK (1) | DK2897945T3 (es) |
EA (1) | EA027281B1 (es) |
ES (1) | ES2617591T3 (es) |
HR (1) | HRP20170352T8 (es) |
HU (1) | HUE032038T2 (es) |
IL (1) | IL237782A (es) |
LT (1) | LT2897945T (es) |
MA (1) | MA37929B1 (es) |
MX (1) | MX367474B (es) |
MY (1) | MY185233A (es) |
NZ (1) | NZ707171A (es) |
PE (1) | PE20150622A1 (es) |
PH (1) | PH12015500414A1 (es) |
PL (1) | PL2897945T3 (es) |
PT (1) | PT2897945T (es) |
RS (1) | RS55779B1 (es) |
SG (1) | SG11201501573UA (es) |
SI (1) | SI2897945T1 (es) |
TN (1) | TN2015000102A1 (es) |
TW (1) | TWI614238B (es) |
UY (1) | UY35041A (es) |
WO (1) | WO2014047372A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104854094A (zh) | 2012-09-21 | 2015-08-19 | 百时美施贵宝公司 | 氟烷基二苯并二氮杂*酮化合物 |
CN104822677A (zh) | 2012-09-21 | 2015-08-05 | 百时美施贵宝公司 | 氟烷基-1,4-苯并二氮杂*酮化合物 |
EP2897944B1 (en) | 2012-09-21 | 2016-10-26 | Bristol-Myers Squibb Company | Substituted 1,5-benzodiazepinone compounds |
UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
WO2014047374A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds |
JP2015529253A (ja) | 2012-09-21 | 2015-10-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Notch阻害剤としてのフルオロアルキルおよびフルオロシクロアルキル1,4−ベンゾジアゼピノン化合物 |
CN104797584A (zh) | 2012-09-21 | 2015-07-22 | 百时美施贵宝公司 | 作为notch抑制剂的三环杂环化合物 |
EP2897941B1 (en) | 2012-09-21 | 2016-09-07 | Bristol-Myers Squibb Company | Prodrugs of 1,4-benzodiazepinone compounds |
US9242940B2 (en) | 2012-09-21 | 2016-01-26 | Bristol-Myers Squibb Company | N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds |
US9492469B2 (en) | 2013-04-04 | 2016-11-15 | Bristol-Myers Squibb Company | Combination therapy for the treatment of proliferative diseases |
EA033423B1 (ru) | 2015-02-03 | 2019-10-31 | Pfizer | Циклопропанбензофуранилпиридопиразиндионы |
BR112020022654A2 (pt) * | 2018-05-06 | 2021-03-09 | Ayala Pharmaceuticals Inc. | Composições de combinação que compreendem compostos de bisfluoroalquil-1,4-benzodiazepinona e métodos de uso das mesmas |
EP3790553A4 (en) * | 2018-05-06 | 2022-04-20 | Ayala Pharmaceuticals Inc. | COMPOSITIONS CONTAINING CD20 INHIBITORS AND BISFLUORAKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THEREOF |
AU2019271044A1 (en) * | 2018-05-15 | 2021-01-14 | Ayala Pharmaceuticals Inc. | Compositions comprising bisfluoroalkyl-l,4-benzodiazepinone compounds for treating adenoid cystic carcinoma |
MX2020012281A (es) * | 2018-05-15 | 2021-01-29 | Bristol Myers Squibb Co | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. |
JP2021526517A (ja) * | 2018-05-24 | 2021-10-07 | アヤラ ファーマシューティカルズ インコーポレイテッド | ビスフルオロアルキル−1,4−ベンゾジアゼピノン化合物および免疫療法剤を含む組成物ならびにそれらの使用方法 |
EP3860562A1 (en) | 2018-10-02 | 2021-08-11 | Frequency Therapeutics, Inc. | Pharmaceutical compositions comprising otic therapeutic agents and related methods |
TW202103692A (zh) | 2019-04-08 | 2021-02-01 | 美商頻率醫療公司 | 用於治療聽力損失之組合物及方法 |
AU2021218456A1 (en) * | 2020-02-16 | 2022-09-22 | Ayala Pharmaceuticals Inc. | Methods of preparing chiral benzodiazepinone derivatives |
WO2022051442A1 (en) | 2020-09-03 | 2022-03-10 | Bristol-Myers Squibb Company | Polymorphs of bis(fluoroalkyl)-1,4-benzodiazepinone compounds and uses thereof |
CN112142629B (zh) * | 2020-10-10 | 2021-09-14 | 西北工业大学 | 3-氨基磺酰基丙氨酸的制备方法 |
EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
US20240041884A1 (en) | 2020-12-07 | 2024-02-08 | Cellestia Biotech Ag | Pharmaceutical Combinations for Treating Cancer |
WO2022253794A2 (en) | 2021-06-02 | 2022-12-08 | Cellestia Biotech Ag | Method for treating an autoimmune and inflammatory disease |
WO2023079132A1 (en) | 2021-11-08 | 2023-05-11 | Cellestia Biotech Ag | Pharmaceutical combinations for treating cancer |
EP4223292A1 (en) | 2022-02-07 | 2023-08-09 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
WO2024036097A1 (en) | 2022-08-12 | 2024-02-15 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether compounds and isotopologues thereof |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5324726A (en) | 1989-12-18 | 1994-06-28 | Merck & Co., Inc. | Benzodiazepine analogs |
US5852010A (en) | 1996-04-03 | 1998-12-22 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
CA2250203A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6635632B1 (en) | 1996-12-23 | 2003-10-21 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
HRP990246A2 (en) * | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
NZ525513A (en) * | 1998-08-07 | 2004-09-24 | Pont Pharmaceuticals Du | Succinoylamino lactams as inhibitors of Abeta protein production |
US6737038B1 (en) | 1998-11-12 | 2004-05-18 | Bristol-Myers Squibb Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
EP1129355B1 (en) | 1998-11-12 | 2005-07-20 | Bristol-Myers Squibb Pharma Company | Use of radioligands to screen inhibitors of amyloid-beta peptide production |
WO2000038618A2 (en) | 1998-12-24 | 2000-07-06 | Du Pont Pharmaceuticals Company | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
ATE258439T1 (de) | 1999-04-30 | 2004-02-15 | Univ Michigan | Verwendung von benzodiazepinen zur behandlung von apoptose-induzierten autoimmunerkrankungen |
US6960576B2 (en) | 1999-09-13 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production |
US6503902B2 (en) | 1999-09-13 | 2003-01-07 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production |
CA2387493A1 (en) | 1999-10-08 | 2001-04-19 | Lorin Andrew Thompson | Amino lactam sulfonamides as inhibitors of a.beta. protein production |
US6756511B2 (en) | 2000-01-24 | 2004-06-29 | Merck Sharp & Dohme Limited | Gamma-secretase inhibitors |
WO2001060826A2 (en) * | 2000-02-17 | 2001-08-23 | Bristol-Myers Squibb Pharma Company | SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
US6495540B2 (en) | 2000-03-28 | 2002-12-17 | Bristol - Myers Squibb Pharma Company | Lactams as inhibitors of A-β protein production |
AU2001251147A1 (en) | 2000-03-31 | 2001-10-15 | Dupont Pharmaceuticals Company | Succinoylamino heterocycles as inhibitors of abeta protein production |
BR0107532A (pt) | 2000-04-03 | 2004-11-03 | Bristol Myers Squibb Pharma Co | Composto, uso do composto, método para o tratamento de disfunções neurológicas associadas com a produção de b-amilóide, método de inibição da atividade de y-secretase e composição farmacêutica |
MXPA02009729A (es) | 2000-04-03 | 2003-03-27 | Bristol Myers Squibb Pharma Co | Lactamas ciclicas como inhibidores de la produccion de la proteina a-beta. |
GB0008710D0 (en) | 2000-04-07 | 2000-05-31 | Merck Sharp & Dohme | Therapeutic compounds |
AU2001257006A1 (en) | 2000-04-11 | 2001-10-23 | Du Pont Pharmaceuticals Company | Substituted lactams as inhibitors of abeta protein production |
US6878363B2 (en) | 2000-05-17 | 2005-04-12 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
GB0012671D0 (en) | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
BR0106717A (pt) | 2000-06-01 | 2002-04-16 | Bristol Myers Squibb Pharma Co | Compostos, composição farmacêutica e usos dos compostos de lactama inovadora |
US7001901B2 (en) | 2002-08-27 | 2006-02-21 | Bristol-Myers Squibb Company | Tetrazolylpropionamides as inhibitors of Aβ protein production |
WO2004026843A1 (en) * | 2002-09-20 | 2004-04-01 | Arrow Therapeutics Limited | Benzodiazepine derivatives and pharmaceutical compositions containing them |
NZ541324A (en) | 2003-02-04 | 2008-10-31 | Hoffmann La Roche | Malonamide derivatives as gamma-secretase inhibitors |
GB0312365D0 (en) | 2003-05-30 | 2003-07-02 | Univ Aston | Novel 3-substituted-1, 4-benzodiazepines |
DE602004020680D1 (de) | 2003-09-09 | 2009-05-28 | Hoffmann La Roche | Die aktivität von gamma-secretase blockierende malonamidderivate |
EP1795198A1 (en) | 2005-12-09 | 2007-06-13 | Hubrecht Laboratorium | Treatment of Barret's esophagus |
EA017286B1 (ru) | 2007-08-14 | 2012-11-30 | Эли Лилли Энд Компани | Ингибиторы гамма-секретазы |
MA33076B1 (fr) | 2008-01-11 | 2012-03-01 | Hoffmann La Roche | Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer |
TWI530489B (zh) * | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙(氟烷基)-1,4-苯二氮呯酮化合物 |
US9242940B2 (en) * | 2012-09-21 | 2016-01-26 | Bristol-Myers Squibb Company | N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds |
-
2013
- 2013-09-18 TW TW102133985A patent/TWI614238B/zh active
- 2013-09-20 WO PCT/US2013/060790 patent/WO2014047372A1/en active Application Filing
- 2013-09-20 MY MYPI2015700879A patent/MY185233A/en unknown
- 2013-09-20 PT PT137708061T patent/PT2897945T/pt unknown
- 2013-09-20 MA MA37929A patent/MA37929B1/fr unknown
- 2013-09-20 US US14/032,333 patent/US8999918B2/en active Active
- 2013-09-20 SI SI201330507A patent/SI2897945T1/sl unknown
- 2013-09-20 PE PE2015000392A patent/PE20150622A1/es active IP Right Grant
- 2013-09-20 JP JP2015533198A patent/JP6165255B2/ja active Active
- 2013-09-20 ES ES13770806.1T patent/ES2617591T3/es active Active
- 2013-09-20 RS RS20170259A patent/RS55779B1/sr unknown
- 2013-09-20 AR ARP130103390A patent/AR093767A1/es unknown
- 2013-09-20 SG SG11201501573UA patent/SG11201501573UA/en unknown
- 2013-09-20 UY UY0001035041A patent/UY35041A/es active IP Right Grant
- 2013-09-20 HU HUE13770806A patent/HUE032038T2/en unknown
- 2013-09-20 LT LTEP13770806.1T patent/LT2897945T/lt unknown
- 2013-09-20 BR BR112015005817-5A patent/BR112015005817B1/pt active IP Right Grant
- 2013-09-20 CA CA2885574A patent/CA2885574C/en active Active
- 2013-09-20 KR KR1020157006776A patent/KR102155588B1/ko active IP Right Grant
- 2013-09-20 EA EA201590581A patent/EA027281B1/ru not_active IP Right Cessation
- 2013-09-20 EP EP13770806.1A patent/EP2897945B1/en active Active
- 2013-09-20 PL PL13770806T patent/PL2897945T3/pl unknown
- 2013-09-20 CN CN201380048504.4A patent/CN104703976B/zh active Active
- 2013-09-20 DK DK13770806.1T patent/DK2897945T3/en active
- 2013-09-20 MX MX2015003033A patent/MX367474B/es active IP Right Grant
- 2013-09-20 AU AU2013317923A patent/AU2013317923B2/en active Active
- 2013-09-20 NZ NZ707171A patent/NZ707171A/en unknown
-
2015
- 2015-02-20 US US14/627,573 patent/US9273014B2/en active Active
- 2015-02-26 PH PH12015500414A patent/PH12015500414A1/en unknown
- 2015-03-12 CO CO15057524A patent/CO7310522A2/es unknown
- 2015-03-16 IL IL237782A patent/IL237782A/en active IP Right Grant
- 2015-03-17 TN TNP2015000102A patent/TN2015000102A1/fr unknown
- 2015-03-20 CL CL2015000711A patent/CL2015000711A1/es unknown
-
2017
- 2017-03-03 HR HRP20170352TT patent/HRP20170352T8/hr unknown
- 2017-03-16 CY CY20171100338T patent/CY1118739T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR093767A1 (es) | Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona y profarmacos de estos | |
AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
AR105388A1 (es) | Ligandos de difosfina a base de benceno para alcoxicarbonilación | |
AR093515A1 (es) | Triazolopirazinas | |
AR098912A1 (es) | Inhibidores de syk | |
BR112017006253A2 (pt) | novos compostos | |
MX2015015786A (es) | Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il) arilcarboxamida sustituidos y su uso como herbicidas. | |
AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
AR094309A1 (es) | Compuesto heterociclico fusionado y uso del mismo para el control de plagas | |
MX2014013074A (es) | Compuestos de n- (tetrazol-5-il) - y n- (triazol-5-il) arilcarboxamida sustituidos y su uso como herbicidas. | |
AR096837A1 (es) | Heterociclos tricíclicos como inhibidores de proteínas bet | |
AR080057A1 (es) | Piridinas disustituidas como anticancerigenos | |
AR099400A1 (es) | Compuesto heterocíclico fusionado | |
AR100233A1 (es) | Composición de limpieza | |
AR098908A1 (es) | Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4]triazina-1-carboxamida | |
AR097866A1 (es) | Derivados de 4-azaindol | |
AR086829A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
JP2014510816A5 (es) | ||
AR091770A1 (es) | Indolcarbonitrilos moduladores selectivos de receptores androgenicos | |
EA201591486A1 (ru) | Соединения имидазопиридина | |
AR090474A1 (es) | Compuestos de tetrahidropirrolotiazina | |
AR095523A1 (es) | Derivados piridin-4-ilo | |
AR097253A1 (es) | Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida | |
AR099581A1 (es) | Compuestos de aminocarbonilcarbamato | |
MA38884A1 (fr) | Composé de triazolopyridine, compositions et procédés d'utilisation associés |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |